Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -12.00% is 206% below its 5-year average of -3.92%, near the low end of its 5-year range (-12.00%–7.87%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.48% below its 12-month average of -9.49%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -12.00%.
RETURN ON INVESTED CAPITAL (ROIC)
-12.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-9.49%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-5.83%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-3.92%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-26.48%
CURRENT VS 3Y AVG
-105.87%
CURRENT VS 5Y AVG
-205.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.40%
median of 540 covered companies
CURRENT VS SECTOR MEDIAN
+61.77%
vs the sector median at left
Cytek Biosciences, Inc.
Market Cap
$772.27M
Return on Invested Capital (ROIC)
-12.00%
TTM Avg
-9.49%
3Y Avg
-5.83%
5Y Avg
-3.92%
Market Cap
$772.90M
Return on Invested Capital (ROIC)
-23.16%
TTM Avg
-53.28%
3Y Avg
-63.06%
5Y Avg
-59.41%
Market Cap
$773.03M
Return on Invested Capital (ROIC)
-8.34%
TTM Avg
-22.82%
3Y Avg
-51.67%
5Y Avg
-50.32%
Market Cap
$777.55M
Return on Invested Capital (ROIC)
-42.83%
TTM Avg
-51.53%
3Y Avg
-51.53%
5Y Avg
-51.53%
Market Cap
$759.16M
Return on Invested Capital (ROIC)
-38.92%
TTM Avg
-31.45%
3Y Avg
-27.82%
5Y Avg
-24.27%
Market Cap
$788.35M
Return on Invested Capital (ROIC)
3.29%
TTM Avg
2.60%
3Y Avg
-15.46%
5Y Avg
-9.88%
Market Cap
$791.18M
Return on Invested Capital (ROIC)
-0.26%
TTM Avg
4.90%
3Y Avg
-0.53%
5Y Avg
1.15%
Market Cap
$752.12M
Return on Invested Capital (ROIC)
-36.83%
TTM Avg
-41.75%
3Y Avg
-59.42%
5Y Avg
-51.49%
Market Cap
$808.29M
Return on Invested Capital (ROIC)
-9.77%
TTM Avg
8.57%
3Y Avg
-11.39%
5Y Avg
-51.99%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $772.27M | -12.00% | -9.49% | -5.83% | -3.92% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | -23.16% | -53.28% | -63.06% | -59.41% |
| Geron Corporation (GERN)vs › | $773.03M | -8.34% | -22.82% | -51.67% | -50.32% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $777.55M | -42.83% | -51.53% | -51.53% | -51.53% |
| Design Therapeutics, Inc. (DSGN)vs › | $759.16M | -38.92% | -31.45% | -27.82% | -24.27% |
| Mesa Laboratories, Inc. (MLAB)vs › | $788.35M | 3.29% | 2.60% | -15.46% | -9.88% |
| AdaptHealth Corp. (AHCO)vs › | $791.18M | -0.26% | 4.90% | -0.53% | 1.15% |
| Candel Therapeutics, Inc. (CADL)vs › | $752.12M | -36.83% | -41.75% | -59.42% | -51.49% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | -9.77% | 8.57% | -11.39% | -51.99% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $734.60M | -19.45% | -59.05% | -125.75% | -106.53% |
ROIC
-12.0%
ROE
-25.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -12.00% |
| 2026-03-31 | -11.42% |
| 2025-12-31 | -10.35% |
| 2025-09-30 | -7.35% |
| 2025-06-30 | -6.31% |
| 2025-03-31 | -5.91% |
| 2024-12-31 | -4.70% |
| 2024-09-30 | -5.49% |
| 2024-06-30 | -5.96% |
| 2024-03-31 | -6.03% |
| 2023-12-31 | -6.35% |
| 2023-09-30 | -5.99% |
| 2023-06-30 | -4.20% |
| 2023-03-31 | -2.48% |
| 2022-12-31 | -0.38% |
| 2022-09-30 | -0.12% |
| 2022-06-30 | 0.21% |
| 2022-03-31 | 0.70% |
| 2021-12-31 | 1.17% |
| 2021-09-30 | 2.69% |
| 2021-06-30 | 7.87% |
| 2021-03-31 | 7.78% |
| 2020-12-31 | 6.96% |
